PAN Foundation Launches a Financial Assistance Program for Patients Undergoing Radioisotope Treatments for Metastatic Castrate Resistant Prostate Cancer
Washington, DC, May 16, 2013 – Patient Access Network (PAN) Foundation is pleased to announce the creation of a co-pay assistance program addressing the unique needs of patients undergoing radioisotope treatments for metastatic castrate resistant prostate cancer (mCRPC).
According to the Society of Nuclear Medicine, patients suffering from metastatic castrate resistant prostate cancer with advanced tumors that have spread to bone have a poor chance of surviving. The radioisotope treatments of mCRPC improve pain and physical function and may prolong life in patients with castration-resistant prostate cancer and bone metastases. Radioisotope treatments are administered by a set number of providers who have undergone rigorous credentialing and NRC licensing in order to be able to administer such medications.
“PAN is dedicated to providing hope for the most vulnerable underinsured patient populations,” explained Patrick McKercher, PAN President. “Patients being treated with radioisotope treatments for mCRPC have unique and difficult challenges in gaining access to these potentially life-saving therapies – it is our mission to ensure that the cost of these treatments does not interfere with any patient’s ability to begin or continue their course of treatment.”
Qualifying patients are eligible to receive $10,000 per year to cover costs associated with their radioisotope treatments. Patients must have insurance that covers the treatment, must have a household income less than or equal to 500% of the Federal Poverty Level and must reside and receive treatment in the United States.
About Metastatic Castrate Resistant Prostate Cancer
Metastatic Castrate Resistant Prostate Cancer (mCRPC) occurs when prostate cancer has metastasized to other parts of the body (generally the bones), and is no longer responding to hormone treatment or gets worse on hormone therapy. Prostate cancer symptoms can include frequent urination, painful urination and/or ejaculation, blood in urine or semen, weak or interrupted flow of urine, and frequent pain or stiffness in the lower back, hips, or upper thighs. Prostate cancer is the most common cause of death from cancer in men over age 75. Prostate cancer is rarely found in men younger than 40. People who are at a higher risk include: African-American men, men who are older than 60 and men who have a father or brother with prostate cancer.
About the PAN Foundation
Patient Access Network Foundation is dedicated to providing help and hope to patients who would otherwise be unable to afford breakthrough medical treatments. PAN envisions a society in which every individual can access needed medical care, offering hope for a healthy tomorrow. PAN provides assistance through nearly 50 disease-specific programs designed to help patients being treated for certain cancers, chronic illnesses, and rare diseases. Through our streamlined application process and state of the art online tools, we are able to ensure that patients are put on the fast track to therapy.